[
	{
		"en": "As stated in the Code of Conduct for Clinical Trials (Appendix 1.1), this study includes participants of varying age (as applicable), race, ethnicity, and sex (as applicable). The collection and use of these demographic data will follow all local laws and participant confidentiality guidelines while supporting the study of the disease, its related factors,and the IMP under investigation.",
		"cn": "如临床试验实施准则（附录1.1）所述，本研究入组了不同年龄（如适用）、人种、种族和性别（如适用）的受试者。这些人口统计学数据的收集和使用将遵循所有当地法律和受试者保密指南，同时为疾病、其相关因素和在研IMP的研究提供支持。"
	},
	{
		"en": "Prospective approval of protocol deviations to recruitment and enrollment criteria,also known as protocol waivers or exemptions,is not permitted.",
		"cn": "不允许前瞻性批准招募和入选标准的方案偏离（也称为方案豁免或免除）。"
	},
	{
		"en": "An individual is eligible for inclusion in the study if the individual meets all of the following criteria:",
		"cn": "如果受试者符合以下所有标准，则有资格入选本研究："
	},
	{
		"en": "1.Has a diagnosis of ET per WHO diagnostic criteria for myeloproliferative neoplasms (Appendix 9)",
		"cn": "1.根据WHO 骨髓增殖性肿瘤诊断标准诊断为ET（附录9）。"
	},
	{
		"en": "Has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg.an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.Additional requirements for pregnancy testing during and after study intervention are in Section 8.3.5.",
		"cn": "在研究治疗干预首次给药前24小时（对于尿液检测）或72小时（对于血清检测）内，根据当地法规要求进行的高灵敏度妊娠试验（尿液或血清）结果为阴性。如不能确定尿液试验结果为阴性（例如，结果不明确），则需进行血清妊娠试验。在这种情况下，如果血清妊娠结果呈阳性，则必须将受试者从研究中排除。研究干预期间和之后进行妊娠试验的其他要求请参见第8.3.5节。"
	}
]